



---

CSE: DTC

PRESS RELEASE

## DEFENCE THERAPEUTICS ACCUVAC-D001 CANCER VACCINE GENERATES EFFECTIVE LONG-LASTING ANTI-TUMORAL RESPONSE

**Vancouver, BC, Canada, May 25, 2021** – Defence Therapeutics Inc. (“**Defence**” or the “**Company**”), is pleased to announce the completion of its AccuVAC-D001 cancer vaccine pre-clinical study. The AccuVAC-D001 cancer vaccine demonstrated a 70% cure rate of mice with pre-established solid tumors, this AccuVAC-D001 cancer vaccine confirms an effective anti-tumoral response.

Non-specific degradation of endocytosed cancer antigens by endo-lysosomal organelles in dendritic cells (DCs) is a major limitation in the field of cancer vaccination. Defence AccuVAC™ addresses this with its engineered novel antigen formulation. The AccuVAC™ protects endocytosed antigen from non-specific endosomal degradation by promoting its escape via endosomal membrane disruption. As such, endocytosed antigens accumulate - in their closest native state - in the cytosol of DC cells consequently resulting in efficient antigen cross-presentation to responding immune cells.

AccuVAC™ dramatically improved protein processing and cross-presentation by *ex vivo* developed monocyte-derived DCs, which elicited potent CD4 and CD8 T-cell responses compared to the use of naked antigen. The net outcome culminates into effective anti-tumoral responses curing 70% of animals with pre-established solid tumors.

"The solid results of the AccuVAC™ study demonstrates how this strategy can be positively adapted to engineered universal DC vaccines. This puts Defence and its technology on the path for future development of universal therapeutic vaccines for cancer and infectious diseases vaccines", says Mr. Plouffe, CEO of Defence Therapeutics.

Vaccines Market Size 2021, is Projected to Reach USD \$104.87 Billion by 2027, exhibiting a CAGR of 10.7% according to Future Business Insights.

### **About Defence:**

Defence Therapeutics is a publicly-traded biotechnology company working on engineering the next generation vaccines and ADC products using its proprietary platform. The core of Defence

Therapeutics platform is the ACCUM™ technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells. As a result, increased efficacy and potency can be reached against catastrophic illness such as cancer and infectious diseases.

For further information:

Sebastien Plouffe, President, CEO and Director

P: (514) 947-2272

[Splouffe@defencetherapeutics.com](mailto:Splouffe@defencetherapeutics.com)

[www.defencetherapeutics.com](http://www.defencetherapeutics.com)

#### **Cautionary Statement Regarding “Forward-Looking” Information**

This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.

Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.